Tadalafil + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia
Conditions
Benign Prostatic Hyperplasia
Trial Timeline
Dec 1, 2011 → Oct 1, 2012
NCT ID
NCT01460342About Tadalafil + Placebo
Tadalafil + Placebo is a phase 3 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01460342. Target conditions include Benign Prostatic Hyperplasia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01865084 | Phase 3 | Terminated |
| NCT01460342 | Phase 3 | Completed |
| NCT01152190 | Phase 3 | Completed |
| NCT01130532 | Approved | Completed |
| NCT01026818 | Approved | Completed |
| NCT00848081 | Phase 3 | Completed |
| NCT00855582 | Phase 3 | Completed |
| NCT00836693 | Phase 3 | Completed |
| NCT00422734 | Phase 3 | Completed |
| NCT00538564 | Phase 2 | Withdrawn |
| NCT00386009 | Phase 2 | Completed |
| NCT00547625 | Phase 2 | Completed |
| NCT00382135 | Approved | Completed |
| NCT00381732 | Phase 3 | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia